Adults with peanut allergy tolerated and adhered to treatment with a toothpaste that provided oral mucosal immunotherapy, according to a study published in Annals of Allergy, Asthma & Immunology.

Corporate and Financial Updates In April 2025, Invivyd secured a $30 million non-dilutive term loan facility with Silicon Valley Bank, a division of First Citizens Bank, supporting balance sheet ...

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that the results of a nationwide real-world study, published by Dr. Strom ...

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...

Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...

Licensing reports, police records and other documents show dangerous, persistent issues around the dispensing and oversight ...

CHESAPEAKE, VA, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- Fire ants, long known for their painful stings and ...

Submitted NDA for Anaphylm (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of An ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...